LEQEMBI Alzheimer’s Treatment Gets FDA Go Ahead
Phase 2 data showing a reduction in amyloid-beta plaques in early Alzheimer's patients is good enough for FDA to give it temporary approval under their Accelerated Approval pathway.
More reads
New Journalism Tool Reveals How Paid Deniers Dominate The Anti-GMO Movement
A year-long Genetic Literacy Project investigation culminating in the rollout of the Anti-GMO Funding Tracker has found that despite claims that the agro-chemical industry, led by Monsanto, is a…
Mr. Cloud, I Don’t Like You Any More.
My nice Plaxo online address book disappeared when the host company was sold and the buyer discontinued the service. My contacts, up in smoke.
Dropbox (cloud storage and data synch) and TunnelBear…
Journalists Continue To Hope, But There Is No Beecopalypse Or Colony Collapse Disorder
USDA has reported that honeybees are down 4 percent for 2017, which set off another flurry of Beepocalypse claims by corporate journalists who desperately want to believe that modern science is…